Novartis Vaccines and Diagnostics GmbH Sustainability Profile
Novartis Vaccines and Diagnostics GmbH, a prominent player in the biopharmaceutical industry, is headquartered in Germany (DE) and operates extensively across Europe and North America. Founded in 2006, the company has made significant strides in vaccine development and diagnostics, focusing on innovative solutions to combat infectious diseases. Specialising in vaccines and diagnostic tools, Novartis Vaccines is renowned for its commitment to research and development, which has led to the creation of unique products that address critical health challenges. The company has achieved notable milestones, including advancements in vaccine technology and strategic partnerships that enhance its market position. With a strong emphasis on quality and efficacy, Novartis Vaccines and Diagnostics GmbH continues to be a leader in the healthcare sector, contributing to global health initiatives and improving patient outcomes worldwide.
DitchCarbon Score
How does Novartis Vaccines and Diagnostics GmbH's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Novartis Vaccines and Diagnostics GmbH's score of 100 is higher than 99% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Novartis Vaccines and Diagnostics GmbH, headquartered in Germany, currently does not report specific carbon emissions data for the most recent year, as no emissions figures are available. The company is a current subsidiary of Novartis AG, which cascades its climate commitments and initiatives down to its subsidiaries. Novartis AG has established various climate initiatives, including targets set through the Science Based Targets initiative (SBTi), the Carbon Disclosure Project (CDP), and commitments to renewable energy through RE100. These initiatives reflect a corporate commitment to reducing greenhouse gas emissions across its operations, although specific reduction targets for Novartis Vaccines and Diagnostics GmbH have not been detailed. As a subsidiary, Novartis Vaccines and Diagnostics GmbH aligns with the broader climate strategies of Novartis AG, which aims to enhance sustainability and reduce its carbon footprint. However, without specific emissions data or reduction targets at the subsidiary level, the precise impact of these commitments remains unclear.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 583,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 922,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | 000,000,000 | 000,000,000 | 000,000,000 | - | 0,000,000,000 | 0,000,000,000 | 000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
How Carbon Intensive is Novartis Vaccines and Diagnostics GmbH's Industry?
How Carbon Intensive is Novartis Vaccines and Diagnostics GmbH's Location?
Novartis Vaccines and Diagnostics GmbH's Scope 3 Categories Breakdown
Novartis Vaccines and Diagnostics GmbH's Scope 3 emissions, which decreased by 5% last year and increased significantly since 2013, demonstrating supply chain emissions tracking. Nearly all of their carbon footprint comes from suppliers and value chain emissions, representing nearly all emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 78% of Scope 3 emissions.
Top Scope 3 Categories
Novartis Vaccines and Diagnostics GmbH's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Novartis Vaccines and Diagnostics GmbH has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
